This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy
This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes